Immune cells after donor stem cell transplant for blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy (called iNKT cells) given after a donor stem cell transplant for blood cancers. The goal is to see if these cells are safe and can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need to be planning to receive a stem cell transplant from a donor (an allogeneic transplant).
- You should be feeling well enough to do most daily activities on your own (a Karnofsky score above 70).
- You must have a blood cancer such as AML, CML, MDS, or ALL, or another condition that requires a donor stem cell transplant as standard care.
- You can have any type of donor (matched or partially matched) and any conditioning (chemo or radiation) regimen.
- If you have primary myelofibrosis, you may be included in a later part of the study, but not in the first dose level.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.